"On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroe"...
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis
In three double-blind, placebo-controlled clinical trials, 1126 patients with CKD on dialysis received study drug (656 Sensipar, 470 placebo) for up to 6 months. The most frequently reported adverse reactions are listed in Table 1.
Seizures were observed in 1.4% (13/910) of Sensipar-treated patients and 0.7% (5/641) of placebo-treated patients across all completed placebo controlled trials.
Table 1: Adverse Reactions with Frequency ≥
5% in Patients on Dialysis in Short-Term Studies for up to 6 Months
(n = 470) (%)
(n = 656) (%)
|Pain Chest, Non-Cardiac||4||6|
|Dialysis Access Site Infection||4||5|
|*Included are events that were reported at a greater incidence in the Sensipar group than in the placebo group.|
In a randomized, double-blind placebo controlled study of 3,883 patients with secondary HPT and CKD receiving dialysis in which patients were treated for up to 64 months (mean duration of treatment was 21 months in the Sensipar group), the most frequently reported adverse reactions (incidence of ≥ 5% in the Sensipar group and a difference ≥ 1% compared to placebo) are listed in Table 2.
Table 2: Frequency of
Adverse Reactions in Dialysis Patients Treated for up to 64 Months in a
|Adverse Reactio||Placebo (N=1923)||Sensipar (N=1938)|
|3699 subject-years||4044 subject-years|
|Percent of subjects reporting Adverse Reactions (%)||90.9||93.2|
|Abdominal pain upper||6.3||8.2|
|Upper respiratory tract infection||6.3||7.6|
|1Adverse reactions that occurred in ≥ 5% Frequency in
the Sensipar group and a difference ≥ 1% compared to the placebo group
(Safety Analysis Set)
Crude incidence rate = 100 * Total number of subjects with event/ N
N=Number of subjects receiving at least one dose of study drug
Additional adverse reaction rates from the long-term, randomized, double-blind placebo controlled study for Sensipar versus placebo are as follows: seizure (2.5%, 1.6%), rash (2.2%, 1.9%), hypersensitivity reactions (9.4%, 8.3%).
Parathyroid Carcinoma and Primary Hyperparathyroidism
The safety profile of Sensipar in these patient populations is generally consistent with that seen in patients with CKD on dialysis. Forty six patients were treated with Sensipar in a single arm study, 29 with Parathyroid Carcinoma and 17 with intractable pHPT. Nine (20%) of the patients withdrew from the study due to adverse events. The most frequent adverse reactions and the most frequent cause of withdrawal in these patient populations were nausea and vomiting. Severe or prolonged cases of nausea and vomiting can lead to dehydration and worsening hypercalcemia so careful monitoring of electrolytes is recommended in patients with these symptoms.
Eight patients died during treatment with Sensipar in this study, 7 with Parathyroid Carcinoma (24%) and 1 (6%) with intractable pHPT. Causes of death were cardiovascular (5 patients), multi-organ failure (1 patient), gastrointestinal hemorrhage (1 patient) and metastatic carcinoma (1 patient). Adverse events of hypocalcemia were reported in three patients (7%).
Seizures were observed in 0.7% (1/140) of cinacalcet-treated patients and 0.0% (0/46) of placebo-treated patients in all clinical studies.
Table 3: Adverse Reactions with Frequency ≥ 10%
in a Single Arm, Open-Label Study in Patients with Primary Hyperparathyroidism
or Parathyroid Carcinoma
|Number of Subjects Reporting Adverse Reactions||28 (97)||17 (100)||45 (98)|
|Nausea||19 (66)||10 (59)||29 (63)|
|Vomiting||15 (52)||6 (35)||21 (46)|
|Paresthesia||4 (14)||5 (29)||9 (20)|
|Fatigue||6 (21)||2 (12)||8 (17)|
|Fracture||6 (21)||2 (12)||8 (17)|
|Hypercalcemia||6 (21)||2 (12)||8 (17)|
|Anorexia||6 (21)||1 (6)||7 (15)|
|Asthenia||5 (17)||2 (12)||7 (15)|
|Dehydration||7 (24)||0 (0)||7 (15)|
|Anemia||5 (17)||1 (6)||6 (13)|
|Arthralgia||5 (17)||1 (6)||6 (13)|
|Constipation||3 (10)||3 (18)||6 (13)|
|Depression||3 (10)||3 (18)||6 (13)|
|Headache||6 (21)||0 (0)||6 (13)|
|Infection Upper Respiratory||3 (10)||2 (12)||5 (11)|
|Pain Limb||3 (10)||2 (12)||5 (11)|
|N=Number of subjects receiving
at least one dose of study drug.
In a randomized double-blind, placebo-controlled study of 67 patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery, the most common adverse reactions are listed in Table 4.
Table 4: Adverse Reactions
Occurring in ≥ 10% of Subjects in a Double-Blind, Placebo-Controlled
Study in Patients with Primary Hyperparathyroidism
(N = 34)
(N = 33)
|Nausea||6 (18)||10 (30)|
|Muscle spasms||0 (0)||6 (18)|
|Headache||2 (6)||4 (12)|
|Back pain||2 (6)||4 (12)|
|N=Number of subjects receiving at least one dose of study drug Coded using MedDRA version 16.0|
In 26-week studies of patients with secondary HPT and CKD on dialysis 66% of patients receiving Sensipar compared with 25% of patients receiving placebo developed at least one serum calcium value less than 8.4 mg/dL, whereas, 29 % of patients receiving Sensipar compared with 11% of patients receiving placebo developed at least one serum calcium value less than 7.5 mg/dL. Less than 1% of patients in each group permanently discontinued study drug due to hypocalcemia.
In a randomized, double-blind, placebo-controlled study in patients with secondary HPT and CKD receiving dialysis in which patients were treated for up to 64 months (mean duration of treatment was 21 months in the cinacalcet group), 75% of patients receiving Sensipar compared with 29% of patients receiving placebo developed at least one serum calcium value less than 8.4 mg/dL and 33% of cinacalcet patients compared with 12% of patients receiving placebo had at least one serum calcium value less than 7.5 mg/dL. Most of the cases of severe hypocalcemia less than 7.5mg/dL (21/33=64%) occurred during the first 6 months. In this trial, 1.1% of patients receiving Sensipar and 0.1% of patients receiving placebo permanently discontinued study drug due to hypocalcemia.
During a placebo-controlled part of a 52-week study in patients with primary HPT who met criteria for parathyroidectomy on the basis of corrected total serum calcium ( > 11.3 mg/dl [2.82 mmol/L] and ≤ 12.5 mg/dl [3.12 mmol/L]), serum calcium less than 8.4 mg/dL was observed in 6.1% (2/33) of Sensipar treated patients and 0% (0/34) of placebo treated patients.
Postmarketing Experience With Sensipar
The following adverse reactions have been identified during postapproval use of Sensipar. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Rash and hypersensitivity reactions (including angioedema, and urticaria), and myalgia have been identified as adverse reactions during post approval use of Sensipar. Isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia have been reported in Sensipar-treated patients with impaired cardiac function in postmarketing safety surveillance [see WARNINGS AND PRECAUTIONS].
Read the Sensipar (cinacalcet) Side Effects Center for a complete guide to possible side effects
Strong CYP3A4 Inhibitors
Cinacalcet is partially metabolized by CYP3A4. Dose adjustment of Sensipar may be required if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole). The iPTH and serum calcium concentrations should be closely monitored in these patients [see CLINICAL PHARMACOLOGY].
Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see CLINICAL PHARMACOLOGY].
Read the Sensipar Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 12/11/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Sensipar Information
Sensipar - User Reviews
Sensipar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.